Clinical Trial

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Recruiting
View on ClinicalTrials.gov →
Summary
This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.
Protocol Amendment History 23 amendments
This ClinicalTrials.gov record has been amended 23 times since 2022-11-28; most recent amendment 2026-03-03.
Status change: Not Yet Recruiting → Recruiting 2023-09-20
Trial Details
NCT Number NCT05640102
Lead Sponsor BeiGene
Conditions Waldenstrom Macroglobulinemia
Enrollment 111 participants
Start Date 2023-03-03
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-07